Price$2.06+0.02 (+1.23%)
02:15 PM07:15 PM
News · 26 weeks240%
2025-12-142026-06-07
Mix2190d
- Insider10(48%)
- SEC Filings6(29%)
- Other4(19%)
- Leadership1(5%)
Latest news
25 items- SECSEC Form 6-K filed by NuCana plc6-K - NuCana plc (0001709626) (Filer)
- SECSEC Form 6-K filed by NuCana plc6-K - NuCana plc (0001709626) (Filer)
- PRNuCana Appoints Ian Webster as Chief Financial OfficerEDINBURGH, United Kingdom, June 01, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Ian Webster as Chief Financial Officer, effective today. Ian has served as Interim Chief Financial Officer since June 2025 and was previously Director of Finance since joining NuCana in 2019. "We are delighted to appoint Ian as Chief Financial Officer," said Hugh S. Griffith, Founder and Chief Executive Officer of NuCana. "Since joining NuCana, Ian has demonstrated deep financial expertise and a thorough understanding of our b
- SECSEC Form 6-K filed by NuCana plc6-K - NuCana plc (0001709626) (Filer)
- PRNuCana Reports First Quarter 2026 Financial Results and Provides Business UpdateFinal Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026 NUC-7738 Receives FDA IND Clearance: Planned Initial Studies to Focus on Melanoma Advancing Additional Indications and Combination Strategies Cash Runway Expected to Extend into 2029 EDINBURGH, United Kingdom, May 14, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") today announced financial results for the first quarter ended March 31, 2026 and provided an update on its clinical development program with its two lead anti-cancer medicines. "We are pleased to report continued progress in the first quarter of 2026 as NUC-7738 advances towards important clinical and regulatory milestones,"
- SECSEC Form 6-K filed by NuCana plc6-K - NuCana plc (0001709626) (Filer)
- INSIDERSEC Form 4 filed by Bruce Theresa Margaret Ms4 - NuCana plc (0001709626) (Issuer)
- INSIDERSEC Form 3 filed by new insider Levy Elliott M.3 - NuCana plc (0001709626) (Issuer)
- INSIDERSEC Form 3 filed by new insider Harrison David James3 - NuCana plc (0001709626) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mellish Martin C.B.3 - NuCana plc (0001709626) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bloss Jeffrey D.3 - NuCana plc (0001709626) (Issuer)
- SECSEC Form S-8 filed by NuCana plcS-8 - NuCana plc (0001709626) (Filer)
- SECSEC Form 20-F filed by NuCana plc20-F - NuCana plc (0001709626) (Filer)
- SECSEC Form 6-K filed by NuCana plc6-K - NuCana plc (0001709626) (Filer)
- PRNuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business UpdateNUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026 Advancing Additional Indications and Combination Strategies Cash Runway Expected to Extend into 2029 EDINBURGH, United Kingdom, March 19, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") today announced financial results for the fourth quarter and year ended December 31, 2025 and provided an update on its clinical development program with its two lead anti-cancer medicines. "We are excited to enter 2026 with significant momentum as we continue to advance the development of our P
- SECSEC Form SCHEDULE 13D filed by NuCana plcSCHEDULE 13D - NuCana plc (0001709626) (Subject)
- INSIDERSEC Form 3 filed by new insider Kay Andrew Martin3 - NuCana plc (0001709626) (Issuer)
- INSIDERSEC Form 3 filed by new insider Webster Ian Alexander3 - NuCana plc (0001709626) (Issuer)
- INSIDERSEC Form 3 filed by new insider Leperlier Cyrille3 - NuCana plc (0001709626) (Issuer)
- INSIDERSEC Form 3 filed by new insider Griffith Hugh3 - NuCana plc (0001709626) (Issuer)
- INSIDERSEC Form 3 filed by NuCana plc3 - NuCana plc (0001709626) (Issuer)
- SECSEC Form 6-K filed by NuCana plc6-K - NuCana plc (0001709626) (Filer)
- PRNuCana Appoints Theresa Bruce as Chief Operating OfficerEDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief Operating Officer, effective January 1, 2026. "We are delighted to appoint Theresa as Chief Operating Officer and welcome her to NuCana's executive leadership team," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Theresa brings more than two decades of experience leading global clinical development programs across biotechnology companies and clinical research organizations. Her operational leade
- SECSEC Form 6-K filed by NuCana plc6-K - NuCana plc (0001709626) (Filer)
- SECSEC Form 6-K filed by NuCana plc6-K - NuCana plc (0001709626) (Filer)
NCNA FAQ
7 questionsWhat does NuCana plc do?
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase III clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the...Where does NCNA stock trade?
NuCana plc (NCNA) is listed on NASDAQ.What sector and industry is NCNA in?
NuCana plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did NuCana plc go public?
NuCana plc (NCNA) completed its IPO in 2017.What are analysts saying about NCNA?
NuCana plc has had 3 recent analyst actions on file. The most recent action was from William Blair: Mkt Perform on 2024-08-30. Recent price targets cluster around $900.00.What companies are similar to NCNA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NCNA side-by-side with any of them on Quantisnow.How can I track NCNA on Quantisnow?
Quantisnow aggregates NuCana plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NCNA to receive live email and push alerts on every new disclosure.